Article Text


Extended report
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
  1. Ronald van Vollenhoven1,2,
  2. Alexandre Voskuyl2,
  3. George Bertsias3,
  4. Cynthia Aranow4,
  5. Martin Aringer5,
  6. Laurent Arnaud1,
  7. Anca Askanase6,
  8. Petra Balážová7,
  9. Eloisa Bonfa8,
  10. Hendrika Bootsma9,
  11. Dimitrios Boumpas10,
  12. Ian Bruce11,
  13. Ricard Cervera12,
  14. Ann Clarke13,
  15. Cindy Coney14,
  16. Nathalie Costedoat-Chalumeau15,16,
  17. László Czirják17,18,
  18. Ronald Derksen19,
  19. Andrea Doria20,
  20. Thomas Dörner21,
  21. Rebecca Fischer-Betz22,
  22. Ruth Fritsch-Stork19,
  23. Caroline Gordon23,
  24. Winfried Graninger24,
  25. Noémi Györi1,
  26. Frédéric Houssiau25,
  27. David Isenberg26,
  28. Soren Jacobsen27,
  29. David Jayne28,
  30. Annegret Kuhn29,
  31. Veronique Le Guern15,16,
  32. Kirsten Lerstrøm30,
  33. Roger Levy31,
  34. Francinne Machado-Ribeiro31,
  35. Xavier Mariette32,
  36. Jamil Missaykeh33,
  37. Eric Morand34,
  38. Marta Mosca35,
  39. Murat Inanc36,
  40. Sandra Navarra37,
  41. Irmgard Neumann38,
  42. Marzena Olesinska39,
  43. Michelle Petri40,
  44. Anisur Rahman26,
  45. Ole Petter Rekvig41,
  46. Jozef Rovensky42,
  47. Yehuda Shoenfeld43,
  48. Josef Smolen44,45,
  49. Angela Tincani46,
  50. Murray Urowitz47,
  51. Bernadette van Leeuw30,
  52. Carlos Vasconcelos48,
  53. Anne Voss49,
  54. Victoria P Werth50,51,
  55. Helena Zakharova52,
  56. Asad Zoma53,
  57. Matthias Schneider22,
  58. Michael Ward54
  1. 1Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Karolinska Institutet, D1:00 Karolinska University Hospital, Solna, Stockholm, Sweden
  2. 2Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands
  3. 3Department of Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklion, Greece
  4. 4Feinstein Institute for Medical Research, Manhasset, New York, USA
  5. 5Department of Medicine III, University Medical Center TU Dresden, Dresden, Germany
  6. 6New York University, New York, USA
  7. 7LPRe SR—Klub Motýlik, Bratislava, Slovakia
  8. 8Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
  9. 9Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  10. 10Department of Medicine and Joint Academic Rheumatology Program Medical School, National and Kapodestrian University of Athens, Athens, Greece
  11. 11NIHR Manchester Biomedical Research Unit, The University of Manchester and Central Manchester Foundation Trust, Manchester, UK
  12. 12Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain
  13. 13Division of Rheumatology, The Arthritis Society Chair in Rheumatic Diseases Cumming School of Medicine University of Calgary, Calgary, Alberta, Canada
  14. 14Lupus Foundation of America, Washington DC, USA
  15. 15Université Paris-Decartes, Paris, France
  16. 16AP-HP, Hôpital Cochin, service de médecine interne, centre de reference maladies auto-immunes et systémiques rares, Paris, France
  17. 17Department of Rheumatology and Immunology, Institute of Bioanalysis, Institute of Family Medicine, University of Pécs, Pécs, Hungary
  18. 18Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  19. 19Department Rheumatology and Clinical Immunology, University Medical Center, Utrecht, The Netherlands
  20. 20Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy
  21. 21Department Medicine/Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin, Berlin, Germany
  22. 22Polyclinic of Rheumatology, Hiller Research Unit, University Clinic Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany
  23. 23Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
  24. 24Division of Rheumatology, Medical University of Graz, Graz, Austria
  25. 25Service de Rhumatologie, Cliniques universitaires Saint-Luc, Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium
  26. 26Department of Medicine, The Centre for Rheumatology, University College London, UK
  27. 27Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark
  28. 28Department of Medicine, University of Cambridge, Cambridge, UK
  29. 29Interdisciplinary Center for Clinical Trials (IZKS), University Medical Center Mainz, Mainz, Germany
  30. 30LUPUS EUROPE, co-opted trustee for research, Essex UK
  31. 31Rheumatology Department, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
  32. 32Université Paris-Sud; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-sud; INSERM U1184, Le Kremlin Bicêtre, France
  33. 33Bone Densitometry Unit, Monla Hospital, Tripoli, Lebanon
  34. 34Monash University, Faculty of Medicine, Nursing & Health Sciences, Monash Medical Centre, Clayton, Australia
  35. 35Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  36. 36Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
  37. 37University of Santo Tomas, Manila, Philippines
  38., Vienna, Austria
  39. 39Department of Connective Tissues Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
  40. 40Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  41. 41RNA and Molecular Pathology Research Group, Institute of Medical Biology, Health Science Faculty, University of Tromsø, Tromsø, Norway
  42. 42National Institute for Rheumatic Diseases, Piešťany, Slovak Republic
  43. 43Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center (Affiliated to Tel-Aviv University), Tel-Aviv, Israel
  44. 44Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
  45. 452nd Department of Medicine, Hietzing Hospital, Vienna, Austria
  46. 46Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, U.O. Reumatologia e Immunolgia Clinica, Spedali Civili di Brescia, Brescia, Italy
  47. 47Centre for Prognosis Studies in the Rheumatic Diseases, Senior Scientist Krembil Research Institute, Professor Medicine, University of Toronto, Toronto Western Hospital EW 1-409, Toronto, Canada
  48. 48Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, UMIB, Instituto de Ciencias Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal
  49. 49Department of Rheumatology, Odense University Hospital, University of Southern Denmark, Denmark
  50. 50Corporal Michael J. Crescenz VA Medical Center (Philadelphia), Philadelphia, Philadelphia, USA
  51. 51Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
  52. 52Nephrology Unit, City Clinical Hospital n.a. S.P. Botkin, Moscow, Russia
  53. 53Lanarkshire Centre for Rheumatology, Hairmyres Hospital, Scotland, UK
  54. 54National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
  1. Correspondence to Dr Ronald van Vollenhoven, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, 1100 DD, The Netherlands; r.f.vanvollenhoven{at}


Objectives Treat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.

Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.

Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:

1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs).

2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment.

3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.

The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life.

Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.

  • Systemic Lupus Erythematosus
  • Outcomes research
  • Disease Activity

Statistics from


Outcomes in systemic lupus erythematosus (SLE) have improved considerably over the past decades. For the most widely studied specific organ involvement in SLE, lupus nephritis, results from clinical trial follow-up studies demonstrate that the long-term renal survival in this condition has now improved to >90%.1 However, not all outcomes in SLE show the same favourable trends. Most notably, the overall health-related quality of life (HR-QoL) for patients with SLE remains reduced.2 This and other considerations prompted the initiation of the treat-to-target for SLE (T2T/SLE), initiative which over the past several years established an international consensus on the approach to the therapy of SLE based on (1) identifying an appropriate target for each patient; (2) initiating treatment steps to try to achieve this target; (3) assessing the target and (4) adjusting the therapeutic approach, if necessary. These elaborations led to the T2T/SLE recommendations published in 2014.3 One of the most significant targets in SLE was identified as ‘remission of systemic symptoms and organ manifestations’. However, it was recognised by the panel that no generally accepted definition of remission in SLE exists today. Such a definition could be important for basic, clinical and epidemiological studies and clinical trials in lupus, and also for clinical practice. The literature on this topic demonstrates that many clinical trials and observational studies have used a large number of different ad hoc definitions of remission; many of these were reviewed in a recent study.4 Consequently, the T2T/SLE panel identified the definition of remission as a research priority for SLE. In response, an initiative was undertaken in order to achieve consensus in a large multiparty international task force on potential definitions of remission in SLE (DORIS).


An international task force consisting of rheumatologists, nephrologists, dermatologists, clinical immunologists and patient representatives, totalling 60 individuals, was convened. In March 2014, a preliminary meeting was held by a steering committee consisting of 15 of these representatives. The steering committee identified four domains critical to further development of remission definitions; 10 preliminary statements regarding remission that were felt to be uncontroversial; key controversies and a set of proposed topics for further discussion. During the following 4-month period, the 10 preliminary statements were presented to the full task force electronically, deliberated upon by email and then subjected to formal electronic voting. High-level agreement was readily achieved for eight of these, whereas two were placed on the agenda for the subsequent consensus conference. Moreover, an additional number of key topics were identified during these deliberations that were to be dealt with more thoroughly at the face-to-face meeting.

In August 2014, a consensus conference took place where a large majority of the full task force was present. The explicit goal of this consensus conference was to establish guiding principles for working towards a definition of remission in SLE and to formulate proposed definitions that would be amenable to scientific testing. During this meeting, formal votes were taken on a range of points. The level for agreement was set at >90%.

The procedure was informed by the results of the systematic literature review that was carried out in the context of the ‘T2T/SLE’ project3 and was modified and updated in September 2015. We focused on 2 of the 12 original topics of interest that were more relevant to the present study, namely topic #2 (“Have any definitions for low disease activity and remission—both global and organ-specific— been validated as surrogates of therapeutic success against damage accrual, mortality and QoL in SLE?”) and topic #5 (“Is sustained reduction of disease activity or prevention of flares—both general and organ-specific— an achievable goal in SLE?”).3 The literature search was repeated in September 2015 by author GB to include more recently published literature. The PubMed database was searched using index terms and all English-language human studies were evaluated based on the title, abstract and/or full-text. For the purpose of the present study, we report on the systematic literature review results relevant to remission only, which were published since the year 1990 and included ≥70 patients with SLE.


Domains considered critical for defining remission in SLE

Four domains critical for defining remission in SLE were identified: clinical disease activity, serological activity, duration and treatment. Within each of these domains, a number of key issues were identified and these form the basis of the work described here.

Preliminary statements on remission in SLE

Ten statements, considered highly relevant for developing a definition of remission and expected to be uncontroversial, were prepared by the steering committee and subjected to electronic voting by the task force. Eight of these statements readily achieved a high level of consensus (>90%) and are shown in table 1.

Table 1

Preliminary statements on remission in SLE

Therefore, remission is identified as a desirable outcome for patients with SLE with, at the very least, the absence of major symptoms and signs of SLE. Remission is conceived of in terms different from a cure, yet it is also regarded as meaningfully different from a low disease activity state, including the lupus low disease activity state (LLDAS) that has recently been proposed by the Asia-Pacific Lupus Collaboration.5 Perhaps most critically for future work in this area, it is recognised that remission, like LLDAS, has to be a state that, if sustained, is associated with a low likelihood of adverse outcome. To this end, the systematic literature review identified a number of observational studies in patients with lupus nephritis, which illustrate that attainment of (complete) renal remission (or response) (typically defined as a very low level of proteinuria, with normal or stable renal function, with or without inactive urine sediment) is associated with favourable long-term patient and renal outcomes (table 2). Similarly, in general SLE, three retrospective cohort studies have suggested that patients who achieve disease remission have significantly lower rates of damage accrual or mortality after follow-up.

Table 2

Validation of published definitions of disease remission against outcomes in SLE (studies with n ≥70 patients)

Specific agreement was also achieved on the definition of ‘serological activity,’ where it was agreed that there was sufficient support in the literature pertaining to the presence of anti-DNA antibodies and/or hypocomplementemia (defined as above or below the upper limit of normal value for the local laboratory, respectively), but without reference to other autoantibodies. The task force discussed whether definitions of remission should distinguish patients who are serologically active from those who are serologically inactive, as the former are much more likely to experience subsequent flare.4 ,9 No consensus was reached on that statement and the task force suggested to test each of the clinical criteria with and without serology, in order to determine the usefulness of the latter and whether it adds to the construct validity of each definition.

Finally, there was consensus in the task force that treatment with antimalarials does not preclude the patient from being considered to be in remission, even though it is somewhat paradoxical to say ‘off treatment’ when someone is, in fact, taking a medication. However, this step was strongly supported by the task force in respect of the widely held view that antimalarials are often considered long-term maintenance therapy for patients with SLE even if they have achieved remission. Benefits of such treatment are believed to extend beyond flare prevention and disease control, and it was therefore felt incorrect to imply that these medications should be discontinued. The task force does recognise that antimalarials have immunomodulatory effects, and that therefore studies done on patients in remission ‘off treatment’ (by the above definition) may in some instances have to distinguish clearly between those patients who are and who are not taking antimalarials. This would perhaps seem most important for studies of an immunological or pathophysiological nature. A similar argument does of course also apply to medications that do not fall in the above categories but that have or may have immunomodulatory properties, such as statins and vitamin D.

It was also agreed upon by all that patients who are treated with moderate-dose or high-dose glucocorticoids cannot be considered to be in remission, even if they would fulfil other criteria for remission. The main argument for this is the well-established adverse health consequence of long-term moderate-dose to high-dose glucocorticoid treatment.

Two statements were felt to be uncontroversial by the steering committee but did not achieve >90% agreement in the larger task force. One of these, “A definition of remission in SLE must be reasonably consistent with the use of this term in the literature” was intended by the steering committee as indicating that a definition of remission must be aligned with what historically has been considered to be a remission. However, this statement was felt to be a bit too circular by some, given that the literature is divided on the definition of remission.

The statement “Durability in time can be added to any definition of remission in order to define a ‘durable remission’—but need not be included in the definition of remission itself” achieved 86% agreement by premeeting electronic voting. Notably, although a few of the published definitions included in table 2 have incorporated a ‘duration’ component (ranging from 6 months to 5 years), the majority to the studies has not examined the prognostic importance of duration of remission against long-term patient outcomes. When discussed face-to-face by the full task force, an increasing number of delegates were unable to support this statement. After discussion, the vote was 65% in favour—not sufficient to declare consensus. The main arguments for and against this statement, as they were discussed during the meeting, are given in table 3.

Table 3

Arguments for and against the statement “Durability in time can be added to any definition of remission in order to define a ‘durable remission’ but need not be included in the definition of remission itself”

The framework for a definition

The task force discussed what form a definition of remission in SLE should take. A literature search on this topic identified many observational studies and clinical trials that used a large number of different ad hoc definitions of remission in general SLE (see online supplementary appendix table S1) and in lupus nephritis (see online supplementary appendix table S2). After extensively reviewing various options, and with particular attention to the discussion described above regarding duration, the following three key principles were agreed upon (summarised in table 4):

  1. The task force achieved consensus (93%) for the principle that remission in SLE will be defined using the following format:

    “Remission in SLE is a durable state characterized by …. (followed by a reference indicating the absence of symptoms, signs or abnormal labs)”.

    It can be recognised that this definition is to some extent a compromise because it does not specify the length of time during which a remission would have to be sustained in order to qualify. This is a direct result of the fact that no agreement on this could be achieved and that the task force felt that further scientific studies are needed to define the optimal duration for any statement of remission in SLE. A further area of uncertainty was whether the absence of active serology would be required and yet again it was felt that this could be investigated in the future. It should therefore also be recognised that ‘abnormal labs’ in the above statement refers to routine laboratory assessments and not necessarily to anti-DNA antibodies or complement levels.

  2. The task force spent much time on finding correct formulations for defining the absence of clinical signs and symptoms for use in a definition and agreed, in the end, that for this a validated index must be used (98% agreement). The task force specifically suggests that the following can be considered: clinical SLEDAI=0; BILAG 2004 D or E categories only or clinical ECLAM=0. Furthermore, it is recommended that each of these indices is supplemented with the requirement for the physician's global assessment (PhGA) to be below a certain level: in the case of a PhGA ranging from 0 to 3 that should be <0.5. Note that in all instances the term ‘clinical’ for SLEDAI and ECLAM refers to symptoms, signs and routine laboratory testing and disregarding only the points that can be given for the presence of anti-DNA antibodies and/or low complement. The task force also discussed the possibility of defining remission in terms of specific symptoms and signs, such as was done for the proposed definition of remission in paediatric SLE, where certain symptoms and signs are ‘allowed’ for patients with SLE who are nevertheless considered to be in remission.38 Although a minority of participants favoured this approach, there was a more widespread feeling that not using validated indices would to some extent be retrograde, and that practice in various research settings would also increasingly be dominated by the use of such indices.

  3. The task force recommends that a distinction should be made between ‘remission off therapy’ and ‘remission on therapy’ (100% agreement). These two descriptors were chosen in preference to many other suggested terms, some of which are: ‘complete’ versus ‘partial’ remission; ‘complete’ versus ‘clinical’ remission; ‘remission’ versus ‘lupus under control’ or ‘inactive disease’. While there are subtle nuances differentiating between these possibilities, it was considered important to simplify this matter and to strictly limit the number of definitions to two levels of remission.

    In this regard, it is also important that ‘off therapy’ will mean that the patient is on no other immunomodulatory treatment for SLE than possibly antimalarials. As pointed out earlier, for some studies, in particular mechanistic investigations, the immunomodulatory properties of antimalarials must be considered, and in general accurate recording of all medications is recommended.

    ‘Remission on therapy’ will allow some, but not all medications. Specifically, stable immunosuppressives, including biological immunomodulators, are allowed within this level of remission. It was noted that definitions of remission in other autoimmune diseases, including rheumatoid arthritis35 and Crohn's disease,36 do not exclude the chronic use of specific antirheumatic medications, immunosuppressives or biologics. Likewise, these definitions do not limit the use of glucocorticoids. However, in SLE a major contributor to long-term damage and other adverse outcomes is the chronic use of glucocorticoids, and the task force felt that for the patient to be declared in ‘remission on treatment’ the highest allowable dose of glucocorticoids is 5 mg/day prednisone (or equivalent). Prednisone dose thresholds associated with protection from treatment-related harm are currently being studied by several groups and data from those studies should further inform the selection of a threshold glucocorticoid dose in a definition of remission on therapy.

Table 4

The task force's three key recommendations for defining remission in SLE

Further development of the most appropriate definition of remission

The task force discussed in what manner a future definition of remission in SLE could be most thoroughly established.

It was agreed upon by voting that for testing the construct validity of each potential remission definition the most appropriate outcomes are death, damage, lupus flares and HR-QOL measures (100% agreement).

Thus, the task force indicated that any definition of remission in SLE must be tested in terms of the degree to which it correctly identifies patients whose future disease course will be better in these four outcomes. Although mortality remains a key outcome, it is unlikely that many studies will be able to identify this as a differentiating factor. Damage as measured by the systemic lupus international collaborating clinics (SLICC) damage index39 will most likely be the most effective way of ascertaining the construct validity of a definition of remission, as has been provisionally demonstrated for the definition of LLDAS. However, the occurrence of flares, especially severe flares, that can be measured by a variety of instruments,40–42 and measures of HR-QoL will also be important in determining which potential definition of remission in SLE has the greatest validity.

Other points of discussion

Patient's global assessment

There was controversy about the role of the patient's global assessment (PGA) in a remission definition. A majority felt that PGA cannot currently be included pending further research, and specifically that such research is needed to validate PGA as an outcome in reference to remission. Many felt that a better instrument to capture the patient's perspective may be needed. However, patient representatives (authors KL, CC and BvL) were concerned that the patient's perspective was omitted. Indeed, in the T2T recommendations for SLE, both overarching principles and specific recommendations advocate including the patient's perspective in decision-making. However, there is no fully validated measure for the patient's perspective at this time. It was remarked that the PhGA can reflect patient's perspective, and it was proposed to emphasise that PhGA should pay careful attention to patient symptoms, or conversely, that PGA could be a long-term outcome used in the testing of remission definitions; but in formal votes no consensus was reached on these points.

Inclusion of validated skin score

The dermatologists in the task force (authors AK and VPW) suggested to supplement the definition of remission with a validated skin score.

Definition based only on symptoms

A rheumatologist (author MW) pointed out that in as much as the task force is developing possible definitions of remission, a definition based only on symptoms and without the use of an index could also be tested.

Plans for further work and research agenda

The task force agreed upon a plan of work that would include the use of longitudinal datasets from clinical trials, observational studies, registries, etc to test each of the definitions of remission. Likewise, definitions of remission ‘on treatment’ and ‘off treatment’ will be tested separately against the prespecified dependent outcomes indicated above, and different durations of these definitions will also be tested. Moreover, studies done on patients ‘off treatment’ will also record the use of antimalarials and analyse the extent to which this makes a difference. As always, findings in such subanalyses may inform future changes in the proposed definitions.

Proposed durations to be analysed include 6 months, 12 months, 2 years and 5 years.

In addition to this continued work, the task force also recommends specific research to investigate whether definitions of remission are applicable irrespective of genetic backgrounds and/or ethnicity.


An international task force consisting of patient representatives and specialists in clinical immunology, dermatology, nephrology and rheumatology was convened and achieved high-level agreement on eight statements, three key principles and a set of outcomes relating to remission in SLE, thereby providing a road map for further work towards a generally applicable definition.

Remission was approached as a global state, whereas it is recognised that remission can be defined, and has in some instances been defined, at the individual organ system level.

As a conceptual starting-point remission was identified as a desirable outcome for patients with SLE with at the very least the absence of major symptoms and signs of SLE. Remission is considered distinct from a cure and it is also regarded as meaningfully different from a state of low disease activity in SLE such as the LLDAS that has recently been developed by the Asia-Pacific Lupus Collaboration.5 However, the latter definition does not solely require the presence of low disease activity and does therefore, in fact, include both patients who have a low level of disease activity and also those who are in remission.

Perhaps most critically for future work in this area, it is recognised that remission has to be a state that, if sustained, is associated with a low likelihood of adverse outcome.

Regarding treatment, there was consensus that treatment with antimalarials does not preclude the patient from being considered to be in remission, in respect of the recommendation that antimalarials should be considered as long-term maintenance therapy for patients with SLE even if they have achieved remission.3 It was also agreed upon by all that patients who are treated with moderate-dose or high-dose glucocorticoids cannot be considered to be in remission even if they would fulfil other criteria for remission. It is well established that glucocorticoids may suppress signs of disease, but will not achieve bona fide disease control, and also constitute one of the major risk factors for negative outcomes in SLE.

In contrast to these areas of agreement, no consensus could be achieved on two important issues.

First, it transpired that the inclusion of ‘duration’ in a definition of remission was controversial. Some argued that definitions of remission in other disease areas do not have this requirement, and that utility of a definition in clinical studies including clinical trials will be significantly limited if duration is explicitly required. Others argued that remission achieved on only one given point in time lacks clinical relevance in a disease that can be relapsing and remitting. Following lengthy discussion, the task force was able to agree on a compromise using the wording “Remission is a durable state characterised by….” and also clearly identified the need for studies linking the duration of any definition of remission with long-term outcomes.

Second, the task force did not agree on the precise role of the PGA in a remission definition. This issue was debated at considerable length. Several task force members including patient representatives were concerned that the patient's perspective was not explicitly included in the definition, and emphasised the importance of a definition of remission that ‘resonates’ with the patient. However, a majority of the task force felt that while the patient's perspective is critically important in the patient-physician interaction, when it comes to a definition of remission for the purposes of clinical and epidemiological studies and clinical trials, more work is needed in order to either validate PGA as an outcome or more likely to develop a better instrument to capture the patient's perspective. It was pointed out that the physician, when assessing disease activity, is expected to weigh in the patient's perspective.

Additionally, the task force agreed on the definition of ‘serological activity,’ but no consensus was reached regarding whether the latter should be taken into account to define remission. The task force agreed upon the use of longitudinal datasets to determine whether serology adds to the construct validity of each definition.

Nomenclature for remission in SLE was extensively discussed. Many terms were proposed, including ‘complete remission’, ‘partial’ ‘remission’, ‘clinical remission’, ‘serological remission’, ‘lupus under control’, ‘inactive disease,’ etc, many of which were overlapping. In order to simplify matters and achieve consistency, the task force recommends that only one distinction is made between ‘remission off therapy’ and ‘remission on therapy’, where ‘off therapy’ must mean that the patient is on no systemic treatments for SLE other than antimalarials. While ‘remission on antimalarials only’ would be the most accurate term for this state, ‘remission off therapy’ was chosen for brevity and convenience, even though it does allow antimalarial therapy. As stated previously, it will be necessary in future studies to account for the actual use of antimalarials in this group of patients, and subsequent analyses of patients who are and who are not on antimalarials may lead to further distinctions in these categories.

‘Remission on therapy’ will allow stable immunosuppressives, including biologics, and low-dose glucocorticoids. It is of interest to note that the latter type of definition is the more usual in other autoimmune diseases, such as rheumatoid arthritis and Crohn's disease, and would also allow investigators to use the definition in clinical trials.

One limitation of the approach taken by the task force is the decision to limit serological activity to anti-DNA antibodies and low complement. Recent research shows the importance of antibodies to RNA binding proteins to the formation of immune complexes that can stimulate interferon production. Further research may show that, unless these antibodies are assayed, the serological assessment is incomplete.

Finally, the task force recommends a clear research agenda of testing the construct validity of potential remission definitions against death, damage, lupus flares and HR-QOL measures as outcomes (dependent variables) in suitable cohorts of patients. Several task force members have conducted or are conducting such studies. This approach will establish which definition(s) of remission in SLE optimally identifies patients with a better disease course in these four outcomes.

In summary, a set of statements and key principles relevant to remission in SLE were established by an international task force. This work provides a pathway for testing individual definitions against long-term outcomes in order to arrive at a definition of remission in SLE.


The authors wish to acknowledge Ms Lisbeth Löfstrand, Administrator at Karolinska Institutet for her invaluable help during the organisation of the DORIS meetings as well as for manuscript preparation.


View Abstract
  • Lay summary

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • Handling editor Tore K Kvien

  • Twitter Follow Dimitrios T Boumpas at @none

  • Competing interests RvVreports having received Research Support and Grants from AbbVie, Amgen, BMS, GSK, Pfizer, Roche, UCB, and Consultancy or honoraria from AbbVie, Biotest, BMS, Celgene, Crescendo, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, Vertex. LAreports having received travel grants, consultancy or honoraria from Adelphivalues, Amgen, Eli Lilly, GSK, LFB, Menarini France, MSD, Raison de santé.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles